Insight Molecular Diagnostics Inc. Common Stock IMDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23K+11.5% | -$26K+10.3% | -$29K-16.0% | -$25K+13.8% | -$29K+3.3% | ||
| $32K-97.2% | $1.14M+338% | $260K-49.8% | $518K-75.8% | $2.14M+43.9% | ||
| $17K-97.4% | $643K+431% | $121K-28.0% | $168K-79.3% | $813K-6.4% | ||
| $15K-97.0% | $496K+257% | $139K-60.3% | $350K-73.6% | $1.33M+115% | ||
| 46.9%+3.3pp | 43.5%-9.9pp | 53.5%-14.1pp | 67.6%+5.6pp | 62%+20.5pp | ||
| $4.95M-15.0% | $5.83M+50.3% | $3.88M+18.2% | $3.28M+12.2% | $2.92M+29.6% | ||
| $2.4M+4.8% | $2.29M+65.3% | $1.39M-5.1% | $1.46M+21.1% | $1.21M+0.3% | ||
| $2.99M+28.6% | $2.33M-8.6% | $2.55M-3.9% | $2.65M-15.0% | $3.12M+21.7% | ||
| $4.43M-81.5% | $23.93M+114% | $11.19M+9.8% | $10.19M+25.5% | $8.12M-76.3% | ||
| $4.43M-81.5% | $23.93M+114% | $11.19M+9.8% | $10.19M+25.5% | $8.12M-76.3% | ||
| -$4.41M+81.2% | -$23.44M-112% | -$11.05M-12.3% | -$9.84M-44.8% | -$6.8M+79.8% | ||
| -13,790.6%-11,733pp | -2,057.5%+2,192pp | -4,249.2%-2,349pp | -1,900%-1,582pp | -318%+1,945pp | ||
| $123K-74.4% | $480K+147% | $194K+94.0% | $100K-21.9% | $128K+10.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$4.29M+81.3% | -$22.96M-111% | -$10.85M-11.4% | -$9.74M-46.0% | -$6.67M+80.1% | ||
| -13,406.3%-11,391pp | -2,015.4%+2,159pp | -4,174.6%-2,294pp | -1,880.7%-1,569pp | -312%+1,943pp | ||
| -$0.12+83.8% | -$0.74-118% | -$0.34-13.3% | -$0.30-15.4% | -$0.26+88.7% | ||
| -$0.12+83.8% | -$0.74-118% | -$0.34-13.3% | -$0.30-15.4% | -$0.26+88.7% | ||
| 34.5M+13.3% | 30.5M-4.9% | 32M0.0% | 32M+24.6% | 25.7M+96.6% | ||
| 34.5M+13.3% | 30.5M-4.9% | 32M0.0% | 32M+24.6% | 25.7M+96.6% | ||
| -$5.92M— | —— | $3.38M+20.5% | $2.8M+219% | $879K+106% | ||
| -$23K+11.5% | -$26K+10.3% | -$29K-16.0% | -$25K+13.8% | -$29K+3.3% | ||
| $146K-71.1% | $506K+127% | $223K+78.4% | $125K-20.4% | $157K+7.5% | ||
| $32K-97.2% | $1.14M+338% | $260K-49.8% | $518K-75.8% | $2.14M+43.9% | ||
| -$4.41M+81.2% | -$23.44M-112% | -$11.05M-12.3% | -$9.84M-44.8% | -$6.8M+79.8% | ||
| -$3.78M+83.5% | -$22.87M-119% | -$10.46M-12.7% | -$9.28M-47.0% | -$6.32M+80.9% | ||
| -$3.78M+83.5% | -$22.87M-119% | -$10.46M-12.7% | -$9.28M-47.0% | -$6.32M+80.9% | ||
| -11,818.8%-9,811pp | -2,008.1%+2,017pp | -4,024.6%-2,233pp | -1,792.1%-1,497pp | -295.4%+1,931pp | ||
| -$4.41M+81.2% | -$23.44M-112% | -$11.05M-12.3% | -$9.84M-44.8% | -$6.8M+79.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insight Molecular Diagnostics Inc. Common Stock's revenue?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated $1.9M in revenue over the trailing twelve months, down 49.3% year over year.
- Is Insight Molecular Diagnostics Inc. Common Stock profitable?
- Insight Molecular Diagnostics Inc. Common Stock is not currently profitable: it reported a net loss of $47.8M over the trailing twelve months, a -2454.6% net margin.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Gross margin is 51.3% and operating margin is -2500.7%, with a -2454.6% net margin.
- What is Insight Molecular Diagnostics Inc. Common Stock's earnings per share?
- Insight Molecular Diagnostics Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Insight Molecular Diagnostics Inc. Common Stock's income statement data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
